Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice
Open Access

Tdap vaccination in pregnancy

Daniel Dalcin and Scott A. Halperin
CMAJ June 14, 2021 193 (24) E911; DOI: https://doi.org/10.1503/cmaj.202420
Daniel Dalcin
Faculty of Medicine (Dalcin), Dalhousie University; Departments of Pediatrics, and of Microbiology & Immunology (Halperin); Canadian Centre for Vaccinology, Dalhousie University; IKW Health and Nova Scotia Health, Halifax, NS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott A. Halperin
Faculty of Medicine (Dalcin), Dalhousie University; Departments of Pediatrics, and of Microbiology & Immunology (Halperin); Canadian Centre for Vaccinology, Dalhousie University; IKW Health and Nova Scotia Health, Halifax, NS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Most severe pertussis infections occur in infants

A Canadian study of children (< 17 yr) who were hospitalized for pertusis from 1999–2015 found that infants younger than 2 months had the highest incidence of admission to hospital (116.40, 95% confidence interval [CI] 85.32–147.49 per 100 000 population) and to the intensive care unit (33.48, 95% CI 26.35–40.62 per 100 000 population). All fatal cases of pertussis involved infants aged 3 months and younger.1

Vaccination against tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) in pregnancy has been recommended in Canada since 2018

In 2018, the Canadian National Advisory Committee on Immunization changed their guidance to recommend Tdap vaccination at 27–32 weeks’ gestation in each pregnancy, irrespective of previous immunizations, based on multiple international maternal immunization studies that showed vaccine efficacy.2

Infants receive passive immune protection from maternal Tdap vaccinations during pregnancy

Infants born to mothers immunized with Tdap during pregnancy benefit from transplacental transfer of maternal pertussis antibodies, allowing for immunity in the first months of life, when infants are most at risk of severe pertussis and death.3 A retrospective cohort study involving 148 981 infants found maternal Tdap vaccination was associated with a 91.4% (95% CI 19.5–99.1) reduction in the risk of pertussis among infants in the first 2 months and 69.0% (95% CI 43.6%–82.9%) in the first 12 months of life.4

Tdap vaccination in pregnancy is safe

In 2011, the American College of Obstetricians and Gynecologists began recommending Tdap vaccination during pregnancy. Numerous surveillance studies now support its safety and efficacy. 5 A recent randomized, controlled, observer-blind, multicentre clinical trial showed no difference in rates of maternal–fetal adverse events between patients who received the Tdap vaccine and those who received the tetanus–diphtheria vaccine.6

Cocooning is no longer recommended

Vaccinating family members and close contacts to provide a “cocoon” of protection for the infant is no longer recommended; however, vaccination of individuals who have not previously received the Tdap vaccine is still encouraged.2,5

Footnotes

  • Competing interests: Scott Halperin reports grants from GSK and Sanofi Pasteur related to research on pertussis-containing vaccines, as well as occasionally serving on advisory boards. He also reports payment for expert testimony by the province of Ontario regarding vaccine-associated adverse events. Scott Halperin is a member of a consortium that holds a patent for a novel adjuvant related to pertussis vaccines. He has also served on a clinical trial’s Data Safety Monitoring Board for pertussis vaccines in pregnancy. No other competing interests were declared.

  • This article has been peer reviewed.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

  1. ↵
    1. Abu-Raya B,
    2. Bettinger JA,
    3. Vaderkooi OG,
    4. et al.
    Members of the Canadian Immunization Monitoring Program, Active (IMPACT). Burden of children hospitalized with pertussis in Canada in the acellular pertussis vaccine era, 1999–2015. J Pediatric Infect Dis Soc 2020;9:118–27.
    OpenUrl
  2. ↵
    Update on immunization in pregnancy with Tdap vaccine: Update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine. Public Health Agency of Canada; 2018, modified 2019 Oct. 9. Available: www.canada.ca/en/public-health/services/publications/healthy-living/update-immunization-pregnancy-tdap-vaccine.html (accessed 2021 Mar. 5).
  3. ↵
    1. Abu Raya B,
    2. Edwards KM,
    3. Scheifele DW,
    4. et al
    . Pertussis and influenza immunisation during pregnancy: a landscape review. Lancet Infect Dis 2017;17:e209–22.
    OpenUrlCrossRef
  4. ↵
    1. Baxter R,
    2. Bartlett,
    3. Fireman B,
    4. et al
    . Effectiveness of vaccination during pregnancy to prevent infant pertussis. Pediatrics 2017;139. doi: 10.1542/peds.2016-4091.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. ACOG Committee Opinion 718. Washington (DC): American College of Obstetricians and Gynecologists (ACOG). 2017. Available: www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/09/update-on-immunization-and-pregnancy-tetanus-diphtheria-and-pertussis-vaccination (accessed 2021 Mar. 5).
  6. ↵
    1. Halperin SA,
    2. Langley JM,
    3. Ye L
    . A randomized controlled trial of the safety and immunogenicity of tetanus, diphtheria, and acellular pertussis vaccine immunization during pregnancy and subsequent infant immune response. Clin Infect Dis 2018;67:1063–71.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 193 (24)
CMAJ
Vol. 193, Issue 24
14 Jun 2021
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tdap vaccination in pregnancy
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Tdap vaccination in pregnancy
Daniel Dalcin, Scott A. Halperin
CMAJ Jun 2021, 193 (24) E911; DOI: 10.1503/cmaj.202420

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Tdap vaccination in pregnancy
Daniel Dalcin, Scott A. Halperin
CMAJ Jun 2021, 193 (24) E911; DOI: 10.1503/cmaj.202420
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Most severe pertussis infections occur in infants
    • Vaccination against tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) in pregnancy has been recommended in Canada since 2018
    • Infants receive passive immune protection from maternal Tdap vaccinations during pregnancy
    • Tdap vaccination in pregnancy is safe
    • Cocooning is no longer recommended
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • Immunisation durant la grossesse avec le vaccin DCaT
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Vulvar condyloma lata as a first presentation of syphilis
  • Pregnancy in people living with obesity
  • Bedbugs
Show more Practice

Similar Articles

Collections

  • Article Types
    • Five Things to Know About
  • Topics
    • Infectious diseases
    • Maternal-fetal medicine
    • Pediatrics
    • Vaccination

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire